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Abstract 
Background:  Most people with bipolar disorder (BD) spend a significant percentage of their lifetime 
experiencing either sub-syndromal depressive symptoms or major depressive episodes, which 
contribute greatly to the high levels of disability and mortality associated with the disorder. Despite 
the importance of bipolar depression, there are only a small number of recognised treatment options 
available. Consecutive treatment failures can quickly exhaust these options leading to treatment-
resistant bipolar depression (TRBD). Remarkably few studies have evaluated TRBD and those available 
lack a comprehensive definition of multi-therapy resistant bipolar depression (MTRBD).  
Aim: To reach consensus regarding threshold definitions criterion for TRBD and MTRBD.  
Method: Based on the evidence of standard treatments available in the latest BD treatment 
guidelines, TRBD and MTRBD criteria were agreed by a representative panel of BD experts using a 
modified Delphi method.  
Results: TRBD criteria in bipolar depression was defined as failure to reach sustained symptomatic 
remission for 8 consecutive weeks after two different treatment trials, at adequate therapeutic doses, 
with at least two recommended monotherapy treatments or at least one monotherapy treatment and 
another combination treatment. MTRBD included the same initial definition as TRBD, with the 
addition of failure of at least one trial with an antidepressant, a psychological treatment and a course 
of electroconvulsive therapy.  
Conclusions: The proposed TRBD and MTRBD criteria may provide an important signpost to help 
clinicians, researchers and stakeholders in judging how and when to consider new non-standard 
treatments.  However, some challenging diagnostic and therapeutic issues were identified in the 
consensus process which need further evaluation and research.  
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Background 
The treatment of depressive episodes experienced by people with bipolar disorder (BD) is one of the 
most challenging issues faced by both clinicians and researchers. Most people with BD spend a 
significant percentage of their time experiencing either sub-syndromal depressive symptoms or major 
depressive episodes and these contribute to the high levels of distress, global disability and mortality 
associated with the disorder1,2. There are only a small number of licenced therapeutic options 
available for the treatment of bipolar depression, and these often fail to significantly improve patients’ 
symptoms and functionality3.  Consecutive treatment failures can rapidly exhaust all recommended 
treatment options. It has been suggested that treatment failure rates might be even higher than in 
major depressive disorder (MDD)4. Despite this, there are remarkably few studies which have 
specifically evaluated treatment-resistant bipolar depression (TRBD) and those available lack a 
common definition of TRBD which makes it difficult to generalize their results3,5,6.  Fortunately, during 
the last decade, new promising non-standard treatment options have become available, but they are 
either not currently included in guidelines or are recommended for use only by specialist services. 
These emerging treatments have a limited evidence base to support their general use and some are 
associated with significant risks, costs and invasiveness in comparison to standard treatments. More 
importantly, as there is no clear consensus on the criteria defining TRBD, it is difficult to know at which 
point of the treatment pathway these non-standard interventions might be considered. The few TRBD 
definitions proposed so far vary, and most only consider pharmacological options independently of 
more comprehensive and standardized treatment including psychotherapy, physical therapies and 
lifestyle modification7–9. We have recently published multi-therapy resistance criteria in MDD as a 
guide to when clinicians could consider the use of non-standard treatments10. Adopting a similar 
approach, we first set out to reach a consensus for criteria defining TRBD mainly based on the National 
Institute for Health and Care Excellence (NICE) and the British Association for Psychopharmacology 
(BAP) BD treatment guidelines11,12. The main aim of this study was to reach an agreement about the 
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concept and definition of Multi-therapy resistant bipolar depression (MTRBD), encompassing 
pharmacological treatments as well as psychological and physical treatments. The purpose of 
developing MTRBD criteria was to define a point in the bipolar depression treatment pathway when 
clinicians may wish to consider the use of non-standard treatments, rather than provide specific 
treatment recommendations.  
 
Method 
The development of the criteria definitions followed five successive phases (Figure 1).  Initially, a group 
of UK experts representing all major specialists’ centres and relevant domains of expertise were 
approached and all consented to participate. The initial consensus panel was composed of 18 bipolar 
disorder experts from primary, secondary and tertiary care. Two members of the panel (AHY, PRAS) 
and a facilitator (DHM) developed a first set of TRBD and MTRBD criteria based on the latest NICE and 
BAP treatment guidelines for bipolar disorder which were among the most updated treatment 
guidelines at the time this project started 11,12. These criteria were reviewed and discussed during an 
initial face-to-face and online meeting sponsored by the Royal College of Psychiatrists (London, March 
2018), and challenging issues highlighted were noted while drawing up the initial draft criteria. The 
meeting participants decided that both TRBD and MTRBD criteria were needed to cover the whole 
trajectory and range of possibilities in the course of treating bipolar depression. To ensure that the 
criteria were as consistent and practical as possible, it was agreed that TRBD criteria should be 
embedded as the initial pharmacological treatment stage of the more comprehensive MTRBD criteria 
as a natural continuum of clinical practice.  
 
Feedback and discussion from the initial meeting was incorporated into a new second version of the 
draft criteria. This, and unresolved diagnostic and therapeutic issues, were then rated for their 
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relevance to be included in the criteria and this manuscript through a modified Delphi method13,14. To 
ensure criteria generalizability, during the Delphi process, seven non-UK bipolar disorder experts from 
key representative international societies ((Canadian Network for Mood and Anxiety Treatments 
(CANMAT), International College of Neuropsychopharmacology (CINP), European College of 
Neuropsychopharmacology (ECNP), International Society for Affective Disorders (ISAD), International 
Society for Bipolar Disorders (ISBD), World Federation of the Societies of Biological Psychiatry (WFSBP) 
and the Royal Australian and New Zealand College of Psychiatrists (RANZCP)) were invited to be part 
of the consensus panel. The international representatives invited were previously or currently 
involved in the development of treatment guidelines in their respective societies, which are amongst 
the leading evidence-based international treatment guidelines for BD.  Additionally, in order to include 
the patient’s perspective in the consensus, an expert patient was also invited to anonymously join the 
Delphi process.  An expert patient is a person who has the knowledge needed to play an active role in 
making shared decisions about their own health care and management of their chronic condition15. 
All the international representatives and the expert patient contacted accepted the invitation to be 
involved in the process.  
[Figure 1 goes here] 
The modified Delphi method was conducted using an online survey collecting anonymous responses 
in three rounds. The items included in the surveys were organized in three sections: (1) statements 
about unresolved elements of the second draft TRBD and (2) MTRBD criteria as well as (3) statements 
about challenging diagnostic and treatment issues identified throughout the process. The participants 
rated the surveys items ranging from “Essential”, “Important”, “Don’t know/Depends”, to 
“Unimportant” or “Should not be included”. The first survey round also allowed participants to add 
comments after rating each item, which could include suggestions about other pertinent references, 
studies or treatment guidelines. In each round, the expert patient was offered additional information 
and support to understand and respond appropriately to each item according to their own judgement. 
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After reading and analysing the comments provided by the participants, three of the authors (AHY, 
PRAS, DHM), determined if they contained new information which merited the addition of a new item 
in subsequent Delphi rounds. Survey items were classified as endorsed, re-rated or rejected. 
Endorsement cut-off was set to at least 80% of answers rating an item as essential or important. Items 
rated as essential or important by 65% to 79.9% of the participants were included in the subsequent 
rounds for re-rating. These cut-off criteria have been also used by similar expert consensus using the 
Delphi method in the field14,16. Participants could decide whether they wanted to maintain or change 
their previous rating on these re-rated items only once; if items did not achieve the threshold for 
endorsement or re-rate, they were rejected. After each round, all the aggregated results were sent to 
the participants. Items requiring re-rating after the third round are outlined in the discussion section.   
 
Results 
The initial survey included 33 items (Supplementary material 1), and the second survey included 17 
items of which 3 were items needing re-rating and 14 were new items extracted from the comments 
left by the experts in the first round. All the participants completed the first round of the Delphi survey 
whereas the second and third round were completed by 92.3% (24/26) and 88.5% (23/26) of the panel, 
respectively. In the second round, 7 items were endorsed by the experts, 6 items were excluded and 
4 remained unresolved diagnostic and therapeutic issues which required re-rating. In the final round, 
3 out of the 4 items were endorsed while 1 item remained unresolved.  In total, 15 out of the original 
33 items were endorsed and included in the final criteria (Figure 2).  
[Figure 2 goes here] 
The final consensus reached on the criteria for TRBD and MTRBD are detailed in Table 1 and Table 2.  
[Table 1 goes here] 
[Table 2 goes here] 
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Discussion 
In this study, we reached consensus definitions for both treatment resistant bipolar depression and 
multi-therapy resistant bipolar depression. We hope that these criteria will be a useful guide for 
clinicians when they are considering the use of non-standard treatment options and for researchers 
as a framework to guide future studies.  
It is important to note that these are not the first proposed definitions for treatment resistance in 
bipolar depression. Many previous definitions are based on commonalities in the clinical presentation 
and treatment of bipolar depression and major depressive disorder (MDD)3,5,7,9. Most of these criteria 
include one or two failures to respond to treatments or reach remission to either mood stabilizers 
and/or antidepressants at adequate doses after between 6 and 8 weeks. However, over the last ten 
years, a growing body of evidence has demonstrated marked differences in treatment efficacy of a 
range of treatments, for example SSRI antidepressants, between BD and MDD17, and several studies 
have shown the useful role of quetiapine and lurasidone for the treatment of bipolar depression18.  
In this context, Pacchiarotti et al. previously provided a stepwise series of definitions for treatment 
refractoriness in bipolar depression ranging from treatment-resistant to involutional bipolar7. The first 
step of this definition for bipolar I depression defined treatment resistance as a failure to reach 
remission with adequate plasma levels of lithium (0.8 mEq⁄l) or to other adequate ongoing mood-
stabilizing treatment, plus lamotrigine (50–200 mg⁄day) or with full dose (≥600 mg⁄day) of quetiapine 
as monotherapy (300-600 mg ⁄day allowed for bipolar II depression)7. An adequate trial period to 
reach remission was defined as 8 weeks as in our criteria.  Our criteria contain similar options to those 
of Pacchiarotti, but more explicitly allow for combination therapy and do not require a minimum dose 
of 600mg Quetiapine for bipolar I depression. Since the Pacchiarotti et al criteria, new emerging 
evidence and consensus have been published, especially regarding the use of antidepressants, as well 
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as other standard treatments (i.e. lurasidone)5,16. As a result, guidelines have been updated 
accordingly and these changes have been reflected in our version of the TRBD definition criteria. In 
comparison to previous proposed criteria, our MTRBD criteria were developed with a more pragmatic 
approach but within the initial evidence framework of the latest NICE and BAP guidelines11,12. 
 
TRBD criteria 
The agreed TRBD criteria includes failure to reach sustained remission or tolerate at least two different 
adequate treatment trials, for at least 8 weeks at therapeutic doses with acceptable adherence, of 
monotherapy (quetiapine, lurasidone, lamotrigine or olanzapine/fluoxetine combination), or at least 
one of these as monotherapy and one of these in combination with lamotrigine, valproate or lithium. 
These criteria were mostly based on NICE and BAP bipolar depression guidelines. The number of 
required failed trials was a matter of discussion which required a Delphi round to reach agreement. 
There were concerns that only two trials were a low threshold to consider further treatments, whilst 
on the other hand increasing the number of required treatment trials would extend the time that the 
patient remains symptomatic and inhibit access to other potential beneficial treatments. Treatment 
refractoriness was set as intolerance to treatment or failure to reach symptomatic sustained remission 
after at least eight consecutive weeks with each trial19. For lamotrigine monotherapy, this could be 
considered as eight consecutive weeks at a stable therapeutic dose after an initial dose titration of 
about 6 to 8 weeks. However, the length of this particular trial alongside the controversial evidence 
around its efficacy as monotherapy requires a thoughtful consideration before starting it, balancing 
patients´ symptoms severity and preferences20.  
The possibility of patient´s refusal of at least one of the trials was considered in the Delphi process, 
but was ultimately rejected due to the very low threshold for the definition and operational 
uncertainty of standardizing valid reasons for refusal. Other aspects confirmed by the first Delphi 
round included the minimum dose of quetiapine and minimum lithium plasma levels. In both cases, 
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the panel endorsed the minimum effective dose of 300mg/day for quetiapine and plasma levels of 0.8 
mEQ/L for lithium. In the second round, despite some debate around the issue, the panel decided to 
keep the combination of olanzapine and fluoxetine (OFC) as a treatment option, rather than a more 
generic second generation antipsychotic and antidepressant combination. This takes into account that 
OFC is a licensed combination in the USA for this indication. Although only OFC is included in our 
criteria, we have no reason to believe that other second generation antipsychotic and selective-
serotonin reuptake inhibitors (SSRIs) combinations would not be effective for the treatment of bipolar 
depression; nevertheless, it should be noted that such other combinations have not yet been 
examined in clinical trials. These points are also consistent with other recent international BD 
treatment guidelines21. An additional point which was endorsed by the panel was the safety and 
inefficacy warning about lamotrigine and valproate combination. This combination is not supported 
by the guidelines and, if used, plasma levels and side effects should be closely monitored.  
There were some suggestions for adding other agents among the initial pharmacological options 
which, after reviewing the body of evidence provide by the treatment guidelines adopted for this 
study11,12, as well as experts opinions during the Delphi process, were ultimately rejected. They are 
listed in Supplementary Table 1. Finally, the panel agreed that these criteria should apply to both 
working age and older adults diagnosed with bipolar I or II disorder.  
 
MTRBD criteria 
The MTRBD criteria extends the TRBD criteria by specifying: a trial of bupropion, or a selective SSRI, 
or a serotonin–norepinephrine reuptake inhibitor (SNRI) for at least 8 weeks at therapeutic doses, in 
combination with an anti-manic drug in bipolar I patients , and carefully monitored in both bipolar I 
and II patients; a course of cognitive behavioural therapy (CBT); and a trial of electro-convulsive 
therapy (ECT) (except in the case of contraindications, intolerance or patient refusal).  The main points 
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of controversy during the initial discussion and the Delphi process were the types of antidepressants 
and psychological treatments to include in the MTRBD criteria.  
Even though prior consensus statements about the use of antidepressant monotherapy for bipolar 
depression discouraged their use, antidepressants are still widely used for the treatment of bipolar 
depression worldwide16,22. It has been suggested that the risk of switch to mania should be balanced 
and considered on a case-by-case basis rather than recommending a broad restriction, especially in 
the particular circumstances of TRBD in which options are limited23. In this context, it was initially 
proposed that antidepressants should be avoided in patients with either a previous history of rapid 
cycling, mixed episodes or manic/hypomanic switches or current mixed symptoms and agitation. 
However, the panel did not endorse this as a general rule, but the evidence available in guidelines and 
several comments of the panel emphasised that special care should be taken when antidepressants 
are used for the treatment of bipolar depression11,12. In line with this, the panel agreed that if 
antidepressants are prescribed in bipolar I depression, they should only be used adjunctively with an 
antimanic drug24, whereas in bipolar II depression, monotherapy with antidepressants is acceptable. 
All patients with bipolar depression treated with antidepressants should be warned about risk of 
switch to hypomanic or manic symptoms and should be careful monitored for the emergence of such 
symptoms. The other area where consensus proved harder concerned which classes of 
antidepressants should be considered for the treatment of bipolar depression. The general agreement 
among panel members was to be as pragmatic as possible and not to limit the already few options 
available while balancing the benefit and risks. As a result, SSRIs, SNRIs and bupropion were endorsed 
by the panel in the final Delphi round.     
The other widely debated area for the MTRBD criteria was the inclusion of psychological interventions 
in the treatment process. This is mainly due to the limited evidence on which guidelines recommend 
these interventions for bipolar depression25. The panel agreed that psychological treatments, in 
general, should be included in the criteria, but due to the lack of evidence of efficacy for bipolar 
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depression, only Cognitive Behavioural Therapy (CBT) was endorsed in the last round as a potentially 
useful approach, in particular its behavioural activation component. The inclusion of a structured 
psychoeducation program among the psychological treatments was the only unresolved item not 
reaching endorsement or rejection rates after the three rounds in the Delphi process. Although the 
effectiveness of a psychoeducational intervention to prevent relapses has been extensively 
demonstrated, the evidence is not robust enough for the treatment of acute episodes25.  Nonetheless, 
and depending on the functional and cognitive status of each individual patient who has not received 
this intervention previously, general or brief psychoeducational interventions might be considered as 
an option, especially taking into account the long time required to complete the whole treatment 
trajectory proposed in MTRBD criteria and long-term relapse prevention after the episode has been 
resolved.   
Finally, at least twelve bilateral sessions of ECT was the last therapeutic option included in the MTRBD 
criteria, provided there were no contraindications and it was accepted and tolerated by the patient. 
Otherwise, it was agreed during the panel discussions that this should be considered a failed trial, and 
thus, the criteria for MTRBD would have been fulfilled.  
During the panel discussions a number of diagnostic and therapeutic considerations emerged, which 
are outlined below. 
 
Diagnostic considerations 
Although most treatment guidelines provide recommendations for the management of bipolar 
depression, they provide less clarity about how to address treatment resistance. In reflecting on this, 
the panel provided some theoretical and practical considerations which could be drawn from standard 
clinical practice and guidelines.  
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The first of these is the need to ensure that for people with TRBD or MTRBD a comprehensive medical 
evaluation is conducted. It is important that clinicians exclude primary organic or pharmacologic 
causes for a depressive episode in BD. This should include a medical screening comprising a complete 
physical examination, blood screening and imaging tests when appropriate. Additionally, any already 
existing organic comorbidities and treatment side-effects should be re-assessed to exclude triggering 
or contributing factors. Abnormal test results  or co-morbid conditions should be evaluated and if 
necessary treated by a specialist as appropriate26 .   
Secondly, given the high prevalence of comorbid psychiatric conditions in BD, the assessment of 
psychiatric comorbidities, particularly substance use, personality and anxiety disorders, is critical in 
the treatment of TRBD and MTRBD as they have been shown to have a negative impact on treatment 
outcomes27–29.  In this context, even if the patient is already well known and to the clinician, semi-
structured interviews may be helpful to assist diagnostic co-morbidity assessments30. The co-
occurrence of one or more psychiatric co-morbidities requires a full assessment of its severity and 
specific evidence-based pharmacological and psychological treatments in coordination with 
professionals with expertise in these conditions, if available. Potential depressogenic agents should 
be avoided in the treatment of comorbid conditions, if possible31. However, since co-morbid 
conditions are exclusion criteria in most BD clinical trials, there is little evidence regarding the efficacy 
of commonly used treatments for these patients. 
Finally, the panel considered that it was important to emphasise the need to employ a systematic and 
consistent method to assess the severity of the depressive symptoms, quality of life and functionality 
with standardized scales used throughout the treatment pathway, particularly before and after 
starting new treatments32. This should include continuous and rigorous medication adherence and risk 
assessment, including for psychotic symptoms and suicidality, as standards of clinical practice 11,12.    
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Therapeutic considerations 
 
General health and exercise 
Current guidelines recommend a healthy diet, smoking cessation and regular exercise alongside 
pharmacological and non-pharmacological therapies, with appropriate interventions where possible 
11,12,33,34. Diet, smoking cessation and exercise may benefit physical co-morbidities, the metabolic risk 
factors associated with the use of some pharmacotherapies, and may augment other therapies. 
However, we could not define diet or exercise 'treatment resistance' in TRBD or MTRBD because of 
the limited and heterogeneous evidence base. 
Mixed-states, psychotic and suicidal symptoms 
Even though controversies still exist around the DSM-5 criteria for BD with mixed features, the 
prevalence of mixed features utilizing these criteria has been reported to be as high as one-third of 
bipolar patients suffering a depressive episode35. Hence, we would suggest that screening for mixed 
features should be a priority during the evaluation of depressive symptoms. However, the evidence 
base for the treatment of mixed states is even more limited than for bipolar depression and there are 
no treatments currently approved by the EMA (European Medicines Agency) or FDA (Food and Drug 
Administration) for the treatment of bipolar depression with mixed features. In general terms, BAP 
and NICE as well as other international guidelines such as CANMAT21 and WFSBP36 discourage the use 
of antidepressant treatments in these circumstances. Second-generation antipsychotics, lithium, 
valproate and lamotrigine have been evaluated for the treatment of depression with mixed features 
but not all have demonstrated efficacy in bipolar depression and most evidence is extrapolated from 
unipolar depression. Among them, a recent review of international guidelines reported that 
lurasidone and ziprasidone may be useful in treating acute mixed depression, valproate may be useful 
in the prevention of new mixed episodes,  and lithium and quetiapine may be useful in preventing 
affective episodes of all polarities37. ECT might also deserve a special consideration when mixed 
features are present11.    
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Suicide and self-harm 
Following recommendations of existing guidelines and practice standards, the presence of suicidal 
symptoms mandates an ongoing risk evaluation to determine the most appropriate setting in which 
to continue the treatment. In these cases, a written risk assessment, safety plan and coping strategies 
must be discussed with the patient. Lithium should be considered as one of the first treatment options 
in these situations given its evidence in preventing suicide in the long-term treatment of people with 
BD38. When psychotic or suicidal symptoms are present and persistent, a re-evaluation of treatment 
needs to consider the option of more invasive approaches such as ECT39.    
Treatment across the lifespan 
The available literature for the treatment for bipolar depression in the perinatal period is generally 
limited, which is reflected in the limited information provided in treatment guidelines. Most of the 
recommendations available come from retrospective reports and/or case studies40,41. However, in 
women of childbearing age with a potential mental health condition, general principles should be 
considered in those fulfilling criteria for TRBD-MTRBD according to existing guidelines.  In this group, 
we would like to highlight that the use of sodium valproate is contraindicated in all females of 
childbearing potential unless conditions of a pregnancy prevention programme are met as is detailed 
in the TRBD-MTRBD criteria42,43.   
The panel agreed in the second round of the consensus process that TRBD-MTRBD criteria should only 
be applied to working age and older adults and should not be applied to children and adolescents.  
The main reason for this decision was that there is insufficient evidence in these age groups about the 
response to standard and non-standard treatments for bipolar depression and sometimes uncertainty 
about the bipolar diagnosis and its potential overlap with the symptoms of other conditions. However, 
NICE guidelines recommend following a similar pharmacological approach as for adults, stressing the 
importance of modifying drug treatments according to age and not routinely continuing antipsychotic 
treatment for longer than 12 weeks12. Additionally, these guidelines recommend providing to these 
13 
 
groups, either individual CBT or interpersonal psychotherapy for at least 3 months. Similarly, BAP 
guidelines recommend following the same pharmacological interventions as in working age adults but 
also suggest considering and balancing dosing and potential harms. Nonetheless, BAP treatment 
guidelines emphasize the scarce empirical evidence available to assume a direct extrapolation from 
adult treatments in these age groups and encourages an integrated treatment approach11.  
There is also a dearth of studies and evidence-based clinical guidelines in older adults.  Due to the 
increased rates of organic comorbidities in this population as well as the reduced hepatic and renal 
clearance, to avoid adverse effects, special caution should be taken titrating and adjusting doses as is 
recommended in existing guidelines11,12,44. 
Strengths and limitations 
This is the first study in which both TRBD and the new concept of MTRBD criteria were agreed by a 
diverse but highly qualified group of international experts, including a patient expert, using a 
systematic Delphi consensus process. Our initial TRBD and MTRBD criteria were also based on two of 
the most updated and highest quality ones among BD treatment guidelines at the time this project 
started (November 2017). In comparison to previous definition proposals, our MTRBD consensus 
criteria were developed with a pragmatic approach considering the whole bipolar depression illness 
trajectory within the existing evidence-based pharmacological treatments while also taking into 
account non-pharmacological options.  As a result, the criteria are well supported by standardized 
guidelines and are highly applicable to real-world clinical practice.  However, for the same reasons, 
the criteria may be affected by the limitations and biases of the evidence contained within current 
guidelines. This also limits the generalization of these criteria to other regions of the world where 
treatments included in the criteria might not be available. However, although the initial starting 
criteria were limited to the British guidelines, all panel members could suggest other evidence-based 
treatment options from different treatment guidelines or studies throughout the consensus process. 
14 
 
Currently, there is very limited evidence to guide the management of TRBD.  The evidence that does 
exist comes from remarkably few randomised controlled trials and also open studies, case series and 
reports. Furthermore, the lack of a common TRBD definition used in this research limits the 
generalizability of their results. This is potentially one reason why treatment assumptions based on 
data extrapolated from the treatment of unipolar depressive episodes continue to exist3,5,9.    
There are some obvious limitations inherent to the Delphi method and how we implemented it. First, 
the initial set of TRBD and MTRBD criteria were previously developed and discussed in a panel of 
experts comprising three-quarters of the whole final Delphi participants, leaving the remaining 
members of the panel with fewer possibilities to modify the initial criteria or raise further points. 
However, the first round of the Delphi survey included the possibility to add further comments to each 
item to be considered during subsequent rounds. Secondly, there is also a potential lack of 
heterogeneity in an expert panel from a specific field which could lead to shared bias in the area. To 
balance for this, the initial panel was not limited to secondary and tertiary care participants but also 
included a primary care expert. Additionally, to minimize regional biases and increase the chances of 
generalizability, the participation in the process of international representatives from leading 
professional societies and an expert patient could be considered strengths of this study to overcome 
the above-mentioned issues.  
Finally, it is important to emphasise that the proposed TRBD and MTRBD criteria does not imply 
treatment recommendations that clinicians should follow for therapeutic refractoriness in BD. The 
rationale for our suggested criteria is to help clinicians, researchers and other stakeholders in 
determining when non-standards treatment options could be considered. An overview of the current 
non-standard treatments available for MDD, which might also be extrapolated to bipolar depression, 
is available in our recently published work about the definition of multiple-therapy-resistant MDD10.  
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Conclusion 
This consensus criteria should be considered as a complement to clinical expertise, as well as to the 
resources available and the particular clinical characteristics and preferences of every single person 
experiencing bipolar depression. We hope the MTRBD criteria will guide clinicians, researchers and 
stakeholders in deciding when to consider the use of novel pharmacological and non-pharmacological 
treatments for resistant bipolar depression in the treatment pathway. Among the unresolved 
diagnostic and therapeutic issues, the utility of different antidepressants classes and psychological 
interventions for the treatment of bipolar depression remain as pressing questions urgently needing 
further research.  
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